Clay Siegall’s Role in The Fight Against Cancer
Clay Siegall is one of the founders of Seattle Genetics. This organization deals with biotechnological research focused on helping cancer patients. Siegall is the CEO of Seattle Genetics. Siegall is a trained scientist who majors in cancer therapies. He earned his Ph.D. in Genetics at the George Washington University. He started his career working for Bristol-Myers Squibb Pharmaceutical Research Institute. He worked at the institute as a research investigator. He got promoted to the role of principal scientist before becoming a biotechnology fellow and National Cancer Institute fellow. It is from these humble beginnings that Siegall proceeded to form Seattle Genetics.
Siegall’s and Seattle Genetics
Under Siegall’s leadership, Seattle Genetics have emerged as authorities in the research and production of antibody-drug conjugates. Siegall helped the firm acquire FDA approval for their ADC product named ADCETRIS, in 2011. ADCETRIS joined with Takeda Pharmaceutical resulting in an international product that is recognized in more than 65 countries.
Siegall has led Seattle Genetics into acquiring multiple licenses for its ADC brand. Under Siegall’s leadership, the ADC product has obtained licenses from GlaxoSmithKline, AbbVie, Genentech, and Pfizer. Dr Siegall helped Seattle Genetics raise capital worth more than $1.2 billion through public and private financings. Siegall also played a significant role in organizing and implementing Seattle Genetics IPO in 2001.
Siegall’s Contribution to Cancer Research
Siegall’s accomplishments in cancer research form the basis of his prosperous career. He has dedicated his skills and experience in researching and implementing cutting edge technology in an effort to find a cure for cancer. Siegall’s desire to help cancer patients and alleviate their suffering has motivated him to be at the fore front in the battle for cancer treatment alternatives. Dr Siegall’s efforts in scientific and medical committees have not gone unnoticed. In 2013, he was gifted with an award by the University of Maryland Alumnus of the Year for Math, Computer, and Natural Sciences. In 2012, he received the Pacific Northwest Ernst and Young Entrepreneur of the Year award.
Clay Siegall is the proud owner of 15 patents and is still intent on advancing his cancer research. His publications outline his research and discoveries, and have helped the cancer research community in its quest for better cancer treatments.
Filed under: Cancer